SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized the management of type 2 diabetes mellitus by effectively lowering blood glucose levels through a unique mechanism of inhibiting glucose reabsorption in the renal tubules.